Effect of roflumilast on airway remodelling in a murine model of chronic asthma

Abstract

These results suggest that the administration of roflumilast regulates airway inflammation, AHR, and airway remodelling in a model of chronic asthma. The beneficial effects from roflumilast may be related to the SCF/c-kit pathway.

Novel approaches to the management of noneosinophilic asthma

“…3 and PDE 4 inhibitors. Phosphodiesterase (PDE) 4 inhibitors have immunomodulatory effects on inflammatory cells potentially relevant to the treatment of asthma [Lipworth, 2005;Page and Spina, 2012;Kim et al 2015b]. In an allergen challenge study the oral PDE 4 inhibitor roflumilast attenuated the rise in sputum eosinophils and neutrophil numbers after the late asthmatic response [Gauvreau et al 2011].…”

Ashtma-Chronic obstructive pulmonary disease overlap syndrome (ACOS): current evidence and future research directions

“…Evidence show that asthma patient can also benefit from treatment with roflumilast since it decreases airway inflammation, remodeling and hyperresponsiveness [82,83]. The results are better when combined with montelukast or ICS [82,84].…”

Developments in the field of allergy in 2016 through the eyes of Clinical and Experimental Allergy

“…Roflumilast is a selective, small‐molecule phosphodiesterase 4 (PDE4) inhibitor that has been shown to possess anti‐inflammatory and fibrotic capabilities and is the first PDE4 inhibitor approved for treatment of chronic obstructive pulmonary disease (COPD) . Selective inhibition of PDE4 increases cellular cAMP, reducing immune cell inflammatory processes including chemotaxis, activation, and degranulation, and has been shown to reduce inflammation‐induced airway remdelling Kim et al employed a mouse model of chronic asthma to determine the effect of roflumilast on the development of the manifestations of asthma (airway inflammation, remodelling [GC hyperplasia and pulmonary fibrosis], and AHR) . The authors showed that chronic intranasal exposure of ovalbumin (OVA)‐sensitized BALB/c mice with OVA administration twice a week for 3 months induced the asthma phenotype.…”

“…42,43 Selective inhibition of PDE4 increases cellular cAMP, reducing immune cell inflammatory processes including chemotaxis, activation, and degranulation, and has been shown to reduce inflammation-induced airway remdelling 42,44,45 Kim et al employed a mouse model of chronic asthma to determine the effect of roflumilast on the development of the manifestations of asthma (airway inflammation, remodelling [GC hyperplasia and pulmonary fibrosis], and AHR). 46 The authors showed that chronic intranasal exposure of ovalbumin (OVA)-sensitized BALB/c mice with OVA administration twice a week for 3 months induced the asthma phenotype. Administration of roflumilast during intranasal allergen exposure significantly inhibited airway inflammation (cellular infiltration and cytokine production) and AHR.…”